Skip to main content
Premium Trial:

Request an Annual Quote

ChondroGene Gets Conditional OK to Trade on Toronto Exchange; Will Change Name to GeneNews

NEW YORK (GenomeWeb News) – ChondroGene today said it has received “conditional approval” from Canadian regulators to list its common shares on the Toronto Stock Exchange.
 
The company, which must still file final documentation, said it expects to begin trading its common shares on the TSX by Oct. 31.
 
At that time ChondroGene will change its name to GeneNews and will trade under the symbol GEN, and ChondroGene’s common shares will cease trading on the TSX Venture Exchange.
 
ChondroGene received shareholder approval to change its name at its annual meeting June 12.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.